Edgewise Therapeutics, Inc. EWTX Business Segments — Contracted Research Expense

Similar metrics at other companies

ALMSSingle Reportable — Research And Development Expense

$81.54M-15.6%

ALMSSingle Reportable — Clinical Research Organizations Contract Manufacturing Organizations And Clinical Trials

$40.93M-37.1%

ALMSSingle Reportable — Other Research And Development Expense

$2.37M+3.2%

CLDXSingle Reportable — Research And Development Expense

$73M+38.7%

ALMSSingle Reportable — Research And Development Facilities And Overhead Costs

$5.37M+3.5%

MMSISingle Reportable — Research And Development Expense

$22.61M+0.6%

Questions, answered.

What is Edgewise Therapeutics, Inc.'s business segments — contracted research expense?

Edgewise Therapeutics, Inc. (EWTX) reported business segments — contracted research expense of $23.94M in Q1 2026.

How has Edgewise Therapeutics, Inc.'s business segments — contracted research expense changed year-over-year?

Edgewise Therapeutics, Inc.'s business segments — contracted research expense increased by 12.4% year-over-year, from $21.3M to $23.94M.

What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — contracted research expense?

Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — contracted research expense has grown at a 23.7% compound annual growth rate (CAGR), from $57.5M to $87.99M.

What does business segments — contracted research expense mean?

Represents the costs incurred by the company for outsourced research and development activities, including payments to contract research organizations (CROs) and external laboratories. This metric reflects the company's reliance on external partners to accelerate clinical trials and drug discovery programs. Monitoring this helps investors assess the intensity of R&D outsourcing strategies.